Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa')

British Journal of Cancer

Volumn 86, Issue 9, 2002, Pages 1518-1523

  Magne N ^a   Fischel, J L ^a   Dubreuil, A ^a   Formento, P ^a   Poupon, M F ^b   Laurent Puig, P ^c   Milano, Gérard ^a,c  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSTITUT CURIE   (France)

^c INSERM   (France)

Author keywords

EGFR; MAPK; p53; Tyrosine kinase inhibitor; Zd1839

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL PATHWAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHORESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; COLONIC NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037029703     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600299     Document Type: Article

References (35)

1. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes
2. P53-independent apoptosis induced by cisplatin with ZD1839 (Iressa™) an EGFR-TK inhibitor in an oral squamous cell carcinoma cell line
3. Ras and Rho GTPases: A family reunion
4. The EGFR as a target for anticancer therapy - Focus on cetuximab
5. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
6. P53 alterations predict tumour response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series
7. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing
8. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
9. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa™), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
10. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
11. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
12. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cevical carcinoma cells progress from high to low cisplatin sensitivity
13. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
14. Quantitative immunohistochemical analysis growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
15. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
16. Single-step DGGE-based mutation scanning of the p53 gene: Application to genetic diagnosis of colorectal cancer
17. Tumor necrosis factor α sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy
18. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumours
19. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumours
20. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53
21. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
22. Intercellular junctions: Downstream and upstream of Ras?
23. P53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma
24. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
25. Epidermal growth factor receptor expression and suramin cytotoxicity in vitro
26. Phase II study receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
27. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
28. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation
29. Epidermal growth factor-related peptides and their receptors in human malignancies
30. Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas
31. SH2/SH3 signaling proteins
32. Cell signaling by receptor tyrosine kinases
33. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
34. Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: A parallel with cytogenic pathways of colorectal cancers
35. P53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck